Inserm Transfert Initiative was among the investors in a $12.3m funding round for Aelis Farma, which is working on a new class of drugs for cognitive disorders.

Aelis Farma, a France-based drug developer spun out of Inserm, has raised €11m ($12.3m) in a funding round backed by the research institute’s tech transfer arm, Inserm Transfert Initiative.
The round also included regional funds ACI, Naco and Aelis Innovation, the latter managed by Irdi Soridec Gestion, as well as public investment bank Bpifrance and the regional government of Région Nouvelle Aquitaine.
Founded in 2014, Aelis Farma is working on a new class of drugs – CB1 signalling…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in